Papers
5
Total Citations
159
H-Index
4
About
G. Henning is a radiation oncology researcher whose work has focused predominantly on the application of stereotactic body radiation therapy (SBRT) for prostate cancer, with particular emphasis on optimizing treatment outcomes for low- and intermediate-risk disease. Henning has made significant contributions to understanding how extreme hypofractionation — delivering high radiation doses in fewer treatment sessions — can be safely and effectively administered across diverse clinical settings. Perhaps most notably, Henning's involvement in a landmark multicenter trial examining SBRT for low- and intermediate-risk prostate cancer has garnered 128 citations, reflecting the study's substantial influence on clinical practice and treatment guidelines. This body of work spans more than a decade, tracing outcomes from early toxicity and quality-of-life assessments in 2010 through five-year survival data in 2016 and comprehensive toxicity reporting in 2018. Henning's research consistently prioritizes patient-reported outcomes alongside clinical endpoints, underscoring a commitment to holistic treatment evaluation. More recent work from 2023 investigates long-term relapse risk factors following dose-escalated SBRT, exploring whether treatment de-intensification may be appropriate for certain patient subgroups — a clinically important question as the field moves toward personalized oncology. Collectively, Henning's contributions have meaningfully advanced the evidence base supporting SBRT as a viable, well-tolerated treatment modality for prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5